ExploreWatchlistsPricing
  1. JP-listed companies
  2. CellSource Co.,Ltd.
  3. Financials
  4. Diluted EPS

CellSource Co.,Ltd. (4880)

Market cap
¥7.3B
P/E ratio
-53.2x
CellSource processes blood and fat tissue into therapeutic substances for medical institutions offering regenerative medicine treatments like knee osteoarthritis and infertility care.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndDiluted EPS (JPY)YoY (%)
Oct 31, 20250.5-95.48%
Oct 31, 202412-75.05%
Oct 31, 202347.9-9.53%
Oct 31, 202253+56.24%
Oct 31, 202133.9-21.10%
Oct 31, 202043-68.76%
Oct 31, 2019137.6

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat